Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002)

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of the rheumatic diseases 2002-11, Vol.61 (suppl 2), p.ii2-ii7
Hauptverfasser:	Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Antoni, C E, Bijlsma, J W J, Burmester, G R, Cronstein, B, Keystone, E C, Kavanaugh, A, Klareskog, L
Format:	Artikel
Sprache:	eng
Schlagworte:	aCL ACR American College of Rheumatology ANA Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use anticardiolipin antibody antinuclear antibody Antirheumatic Agents - adverse effects Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - therapy biological agents Biological and medical sciences blocking agents Bones, joints and connective tissue. Antiinflammatory agents Consensus Statement DAS disease activity score disease modifying antirheumatic drug DMARD Drug dosages HAQ-DI Health Assessment Questionnaire disease index Humans interleukin Interleukin-2 - antagonists & inhibitors Medical sciences methotrexate MTX Patients Pharmacology. Drug treatments Rheumatic diseases Rheumatic Diseases - therapy Rheumatoid arthritis TNF TNF inhibitors Toxicity Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor necrosis factor-TNF tumour necrosis factor tumour necrosis factor α VAS visual analogue scale
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!